The potential of epigenomic medicine in cardiology
Posted: 22 June 2021 | Professor John Giannios (Learna) | No comments yet
Advances in genomic medicine are playing an increasingly important role in the field of cardiology. Better analysis and understanding of patient genomic and epigenomic information can enable more personalised patient treatment and medical intervention. Here, Professor John Giannios considers the potential to use genomic medicine to prevent, monitor, diagnose and treat cardiovascular diseases.
Cardiovascular diseases (CVDs) remain the number one cause of global death, killing approximately 18 million patients annually. Unfortunately, these numbers are increasing constantly along with disability adjusted life years (DALYs) – particularly in developed countries. We urgently need new screening, diagnostic, preventive, monitoring and mainly therapeutic approaches based on genomic medicine against CVDs.
Cardiovascular-diseases are multifactorial-disorders and beyond their genetic/genomic pathogenic information which is encoded in the DNA sequence, is the epigenetic/epigenomic pathogenic etiology consisting of protein, RNA and DNA modifications which may be targeted…
Related topics
Drug Development, Epigenetics, Genetic analysis, Genomics, Molecular Targets, Personalised Medicine
Related conditions
Advanced carotid atherosclerotic disease (ACAD), Atherosclerosis, Cancer, cardiac hypertrophy, cardiovascular disease (CVD), Coronary artery disease (CAD), Coronary heart disease, fibrosis, Hypertension, myocardial infarction
Related organisations
GenScript
